{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-003181","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2023-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.170560+00:00","generated_at":"2026-06-17T23:13:48.849345+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dermata Therapeutics closes $5.0M public offering of common stock and warrants","bullets":["Gross proceeds of $5.0M from offering of 1.62M shares (or pre-funded warrants) plus Series A/B warrants at $2.82 exercise price.","Net proceeds approx. $4.2M; H.C. Wainwright acted as placement agent with 7.0% cash fee.","Existing warrants for 235,849 shares amended: exercise price lowered from $21.20 to $2.82, expiry extended to 5 years.","Offering closed March 20, 2023; 60-day lock-up on further equity issuance and one-year variable-rate transaction ban."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-003181","json":"https://secwatch.observer/filing/0001654954-23-003181.json","markdown":"https://secwatch.observer/filing/0001654954-23-003181.md","text":"https://secwatch.observer/filing/0001654954-23-003181.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423003181/0001654954-23-003181-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423003181/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T23:13:48.849345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7d6ff2ca25d7e9a32d1b5a3f44ca0e7c077dd12f","claim":"Dermata Therapeutics, Inc. entered into Purchase Agreement with an investor valued at approximately $4.2 million (effective 2023-03-16).","evidence_excerpt":"On March 16, 2023, Dermata Therapeutics, Inc. (the \" Company \") entered into a securities purchase agreement with an investor (the \" Purchase Agreement \") pursuant to which the Company agreed to sell, in a best efforts public offering (the \" Offering \") priced at the market under Nasdaq rules, an aggregate of (i) 85,000 shares (the \" Shares \") of common stock, par value $0.0001 per share (the \" Common Stock \"), of the Company, (ii) pre-funded warrants (the \" Pre-Funded Warrants \") to purchase up to an aggregate of 1,533,123 shares of Common Stock (the \" Pre-Funded Warrant Shares \"), (iii) Series A warrants (the \" Series A Common Warrants \") to purchase up to an aggregate of 1,618,123 shares of Common Stock (the \" Series A Warrant Shares \"), and (iv) Series B warrants (the \" Series B Common Warrants \" and collectively with the Series A Warrants, the \" Warrants \") to purchase up to an aggregate of 1,618,123 shares of Common Stock (the \" Series B Warrant Shares \" and together with the Ser","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423003181/0001654954-23-003181-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an investor"},{"label":"Value","value":"approximately $4.2 million"},{"label":"Effective","value":"2023-03-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}